New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
|![](https://www.techprohub.com/wp-content/uploads/2016/10/keytruda.png)
Data presented at the ESMO 2016 Congress, the annual meeting of the European Society … and medical oncologist at Memorial Sloan Kettering Cancer Center.